📣 VC round data is live. Check it out!

Pihlajalinna Valuation Multiples

Discover Pihlajalinna's revenue and EBITDA valuation multiples and M&A history, alongside public comparables like Oncoclínicas, Humana, Atrys Health, Mater Dei and more.

Pihlajalinna Overview

About Pihlajalinna

Pihlajalinna Oyj is a private provider of healthcare and wellbeing services in Finland. The company is engaged in the business of providing healthcare and social care services to municipalities, hospital districts, companies, insurance companies, and private persons. The service selection includes general practitioner and medical specialist services, occupational healthcare, social and healthcare outsourcing, fitness center services, responsible doctor, and remote consultation services as well as residential services and staffing services.


Founded

2014

HQ

Finland

Employees

4.4K

Financials (LTM)

Revenue: $732M
EBITDA: $123M

EV

$488M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Pihlajalinna Financials

Pihlajalinna reported last 12-month revenue of $732M and EBITDA of $123M.

In the same LTM period, Pihlajalinna generated $319M in gross profit, $123M in EBITDA, and $39M in net income.

Revenue (LTM)


Pihlajalinna P&L

In the most recent fiscal year, Pihlajalinna reported revenue of $775M and EBITDA of $132M.

Pihlajalinna is profitable as of last fiscal year, with gross margin of 69%, EBITDA margin of 17%, and net margin of 6%.

See analyst estimates for Pihlajalinna
LTMLast FY202320242025202620272028
Revenue$732M$775M$838M$820M$759M
Gross Profit$319M$538M$541M$587M$538M
Gross Margin44%69%65%72%71%
EBITDA$123M$132M$83M$118M$128M
EBITDA Margin17%17%10%14%17%
EBIT Margin9%9%2%6%6%
Net Profit$39M$44M$7M$32M$44M
Net Margin5%6%1%4%6%
Net Debt-$86M---

Financial data powered by Morningstar, Inc.

Pihlajalinna Stock Performance

Pihlajalinna has current market cap of $278M, and enterprise value of $488M.

Market Cap Evolution


Pihlajalinna's stock price is $12.38.

Pihlajalinna share price decreased by 2.2% in the last 30 days, and by 31.7% in the last year.

Pihlajalinna has an EPS (earnings per share) of $1.94.

See more trading valuation data for Pihlajalinna
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$488M$278M-1.2%-2.2%-18.7%-31.7%$1.94

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Pihlajalinna Valuation Multiples

Pihlajalinna trades at 0.7x EV/Revenue multiple, and 4.0x EV/EBITDA.

See NTM and 2027E valuation multiples for Pihlajalinna

EV / Revenue (LTM)


Pihlajalinna Financial Valuation Multiples

As of June 3, 2026, Pihlajalinna has market cap of $278M and EV of $488M.

Pihlajalinna has a P/E ratio of 7.2x.

LTMLast FY202320242025202620272028
EV/Revenue0.7x0.6x0.6x0.6x0.6x
EV/EBITDA4.0x3.7x5.9x4.1x3.8x
EV/EBIT7.7x7.0x26.9x9.2x10.0x
EV/Gross Profit1.5x0.9x0.9x0.8x0.9x
P/E7.2x6.4x41.8x8.7x6.4x
EV/FCF10.3x7.1x7.5x4.7x7.1x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Pihlajalinna Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Pihlajalinna Margins & Growth Rates

Pihlajalinna decreased revenue by 13% and EBITDA by 16% in the last fiscal year.

In the most recent fiscal year, Pihlajalinna reported gross margin of 69%, EBITDA margin of 17%, and net margin of 6%.

See estimated margins and future growth rates for Pihlajalinna

Pihlajalinna Margins

Last FY202420252026202720282029
Gross Margin69%72%71%43%
EBITDA Margin17%14%17%16%
EBIT Margin9%6%6%8%
Net Margin6%4%6%5%
FCF Margin9%13%9%6%

Pihlajalinna Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth(13%)(2%)(7%)(11%)
Gross Profit Growth(46%)8%(8%)(46%)
EBITDA Growth(16%)43%8%(14%)
EBIT Growth(23%)192%(8%)11%
Net Profit Growth(27%)378%37%(27%)
FCF Growth(43%)60%(34%)(43%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Pihlajalinna Operational KPIs

Pihlajalinna's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.

Pihlajalinna's Rule of 40 is 5% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Pihlajalinna's Rule of X is (12%) (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Pihlajalinna
LTMLast FY202320242025202620272028
Rule of 4011%5%---
Bessemer Rule of X1%(12%)---
Revenue per Employee-$0.2M---
Opex per Employee-$0.1M---
S&M Expenses to Revenue-1%1%1%1%
Opex to Revenue-63%62%65%64%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Pihlajalinna Competitors

Pihlajalinna competitors include Oncoclínicas, Humana, Atrys Health, Mater Dei, Medica Sur, Auna, MediClin, Goodwill Pharma, Clinica Las Condes and Monash IVF Group.

Most Pihlajalinna public comparables operate across Hospitals & Clinics.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Oncoclínicas0.9x0.9x56.5x12.1x
Humana0.6x0.6x5.7x5.8x
Atrys Health2.8x2.7x19.4x17.7x
Mater Dei1.5x1.4x5.9x6.6x
Medica Sur1.1x1.1x4.6x5.1x
Auna1.0x1.0x5.0x4.9x
MediClin0.5x0.5x3.8x3.6x
Goodwill Pharma3.0x-11.3x-

This data is available for Pro users. Sign up to see all Pihlajalinna competitors and their valuation data.

Start Free Trial

Acquisitions by Pihlajalinna

Pihlajalinna has acquired 8 companies to date.

Last acquisition by Pihlajalinna was on February 1st 2018. Pihlajalinna acquired Doctagon for $32M (EV/Revenue multiple available to Pro users).

See M&A valuation multiples

Latest Acquisitions by Pihlajalinna

Doctagon
Kymijoen Työterveys Oy
Linnan Klinikka Oy
Röntgentutka Oy
Description
Doctagon is a Finnish provider of occupational health services tailored for private households, enterprises, and public sector clients. The company delivers preventive care, medical consultations, vaccinations, and physiotherapy across its network of clinics in Helsinki, Espoo, and Tampere regions. Doctagon collaborates with municipal authorities on workforce wellness programs and digital health monitoring tools. Established in 2015, it employs multidisciplinary teams including general practitioners, nurses, and ergonomics specialists to address reform-driven challenges in Finland's social health system.
Kymijoen Työterveys Oy is a Kouvola-based occupational health provider serving employers across the Kymenlaakso region in Finland.
-
Röntgentutka Oy is a Tampere-headquartered medical imaging provider operating clinics in Finland with X-ray, ultrasound, panoramic, and cone beam computed tomography equipment. The company delivers diagnostic services for dental, orthopedic, and general radiography, emphasizing rapid scheduling and skilled radiologist interpretations.
HQ CountryFinlandFinlandFinlandFinland
HQ City
Helsinki
Kotka
-
Tampere
Deal Date1 Feb 201831 Jan 201829 Jan 20189 Jan 2018
Valuation$32Mundisclosedundisclosedundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Pihlajalinna acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Pihlajalinna

When was Pihlajalinna founded?Pihlajalinna was founded in 2014.
Where is Pihlajalinna headquartered?Pihlajalinna is headquartered in Finland.
How many employees does Pihlajalinna have?As of today, Pihlajalinna has over 4K employees.
Who is the CEO of Pihlajalinna?Pihlajalinna's CEO is Tuomas Hyyrylainen.
Is Pihlajalinna publicly listed?Yes, Pihlajalinna is a public company listed on Nasdaq Helsinki.
What is the stock symbol of Pihlajalinna?Pihlajalinna trades under PIHLIS ticker.
When did Pihlajalinna go public?Pihlajalinna went public in 2015.
Who are competitors of Pihlajalinna?Pihlajalinna main competitors include Oncoclínicas, Humana, Atrys Health, Mater Dei, Medica Sur, Auna, MediClin, Goodwill Pharma, Clinica Las Condes, Monash IVF Group.
What is the current market cap of Pihlajalinna?Pihlajalinna's current market cap is $278M.
What is the current revenue of Pihlajalinna?Pihlajalinna's last 12 months revenue is $732M.
What is the current revenue growth of Pihlajalinna?Pihlajalinna revenue growth (NTM/LTM) is (6%).
What is the current EV/Revenue multiple of Pihlajalinna?Current revenue multiple of Pihlajalinna is 0.7x.
What is the current EBITDA of Pihlajalinna?Pihlajalinna's last 12 months EBITDA is $123M.
What is Pihlajalinna's EBITDA margin?Pihlajalinna's last 12 months EBITDA margin is 17%.
What is the current EV/EBITDA multiple of Pihlajalinna?Current EBITDA multiple of Pihlajalinna is 4.0x.
What is the current FCF of Pihlajalinna?Pihlajalinna's last 12 months FCF is $48M.
What is Pihlajalinna's FCF margin?Pihlajalinna's last 12 months FCF margin is 7%.
What is the current EV/FCF multiple of Pihlajalinna?Current FCF multiple of Pihlajalinna is 10.3x.
How many companies Pihlajalinna has acquired to date?As of June 2026, Pihlajalinna has acquired 8 companies.
What was the largest acquisition by Pihlajalinna?$32M acquisition of Doctagon on 1st February 2018 was the largest M&A Pihlajalinna has done to date.
In how many companies Pihlajalinna has invested to date?Pihlajalinna hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Pihlajalinna

Lists including Pihlajalinna

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial